Zobrazeno 1 - 10
of 892
pro vyhledávání: '"chidamide"'
Autor:
Xueying Wang, Yan Deng, Guangcui He, Sihan Lai, Yecheng Li, Shan Zhang, Ying He, Ying Han, Lilan Zhang, Yi Su, Fang Liu, Hai Yi
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTObjectives T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) are highly malignant and aggressive hematologic tumors for which there is no standard first-line treatment. Chidamide, a novel histone deacetylase inhibitor, sh
Externí odkaz:
https://doaj.org/article/e3e9b29fdc34431f93e672732b73b647
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundAngioimmunoblastic T-cell lymphoma (AITL) is known for its unfavorable survival prognosis. Chidamide has shown efficacy in relapsed/refractory AITL, but its efficacy in newly diagnosed AITL is uncertainObjectiveThis retrospective research a
Externí odkaz:
https://doaj.org/article/771d84ed3f90473d92b5ecec631c4a1f
Autor:
Guang‐Liang Chen, Kai Xue, Qunling Zhang, Zu‐guang Xia, Jia Jin, Ran Li, Yizhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Publikováno v:
Cancer Medicine, Vol 13, Iss 16, Pp n/a-n/a (2024)
Abstract Background In relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targe
Externí odkaz:
https://doaj.org/article/2ad1fa44c0184b318107224eea500a7a
Autor:
Chunlan Zhang, Juan Xu, Mingyu Gu, Yun Tang, Wenjiao Tang, Jie Wang, Qinyu Liu, Yunfan Yang, Xushu Zhong, Caigang Xu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundChidamide is subtype-selective histone deacetylase (HDAC) inhibitor that showed promising result in clinical trials to improve prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients. However, in real world settings, contradictory r
Externí odkaz:
https://doaj.org/article/78f031b80a46474bb9dc37d61c8b9a00
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundHemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition characterized by hyperinflammation and organ failure, with a high mortality rate. Current first-line treatments for adult patients have limited efficacy and significan
Externí odkaz:
https://doaj.org/article/1f53923298ec41549bda4102a69c93e4
Autor:
Yaxiong Zhang, Zihong Chen, Yu Liu, Liang Han, Wei Jiang, Qiming Wang, Jianhua Shi, Liqin Lu, Jianying Li, Mingjun Zhang, Yan Huang, Yunpeng Yang, Xue Hou, Li Zhang, Jing Li, Wenfeng Fang, Gang Chen
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Combination of chidamide and anti‐PD‐L1 inhibitor produce synergistic anti‐tumor effect in advanced NSCLC patients resistant to anti‐PD‐1 treatment. However, the effect of chidamide plus envafolimab has not been reported
Externí odkaz:
https://doaj.org/article/578cd829c078423493f02155175529a1
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAngioimmunoblastic T-cell lymphoma (AITL) is characterized by high recurrence rates and poor prognosis, and effective first-line treatment is lacking. Recently, histone deacetylase inhibitors (HDACi), such as chidamide, have been found to i
Externí odkaz:
https://doaj.org/article/5a7518d25ad54e489a0fed264b9f9ef5
Autor:
Jinjin Shao, Zhichao Ye, Zeren Shen, Nienwei Liu, Lijiang Zhang, Masashi Tachibana, Zhiqi Xie
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 173, Iss , Pp 116306- (2024)
Clinical resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) remains a significant challenge. Recent studies have indicated that the number of myeloid-derived suppressor cells (MDSCs) increases following gefitinib trea
Externí odkaz:
https://doaj.org/article/aa46c24150404f2bacc0b17e9cfdb627
Publikováno v:
陆军军医大学学报, Vol 45, Iss 16, Pp 1671-1681 (2023)
Objective To explore the effect of vemurafenib (VEM) combined with chidamide (CDM) on cellular senescence in secondary acute myeloid leukemia (sAML). Methods sAML cell lines SKM-1 and MOLM-13 were divided into control group (sAML cells), VEM group (s
Externí odkaz:
https://doaj.org/article/0bc83f2764ec42cea8207668bf64b238
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-19 (2023)
Abstract Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy. Currently, several novel targeted agents, including histone deacet
Externí odkaz:
https://doaj.org/article/8a0e7ded7b2c47a1b6c886cc2649446d